Broad-spectrum carbapenem antibiotics are the last bastion of empirical therapy for resistant gram-negative bacterial infections, and outbreaks of carbapenem-resistant bacterial infection may be associated with greatly increased mortality in the critically ill ([4][1]). Carbapenems (e.g., imipenem,
No takes yet. Share an insight, caveat, or question.
Espedido et al. (2005) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: